Latest News
-
Merck completes US$6.7B acquisition of Terns Pharmaceuticals to strengthen the leukemia drug pipeline
Terns has now become a wholly owned subsidiary of Merck, and its common stock has ceased trading on the Nasdaq Global Select Market.
-
WHO validates Australia as first high-income nation to eliminate trachoma
The achievement places Australia among 63 countries globally and 16 in the WHO Western Pacific Region that have eliminated at least one NTD.
-
Africa CDC establishes African Strategic Advisory Group on Genomics to improve health security across Africa
The inaugural eight-member ASAG brings together experts in pathogen genomics, human genomics, bioinformatics, clinical genetics, precision medicine, ethics, and public health.
-
Pharco Pharmaceuticals launches “Vision for All” to combat glaucoma in Egypt
The program focuses on early detection of eye diseases, with particular emphasis on glaucoma, while also supporting medical outreach through specialized convoys deployed in underserved communities.
-
BioMarin completes US$4.8B acquisition of Amicus Therapeutics to expand rare disease portfolio
The acquisition brings Amicus Therapeutics fully under BioMarin’s global operations, integrating its late-stage and commercial-stage rare disease assets into BioMarin’s established infrastructure.
-
JOOTRH Study warns rising antibiotic resistance is undermining wound care treatment
The study found that resistance to commonly prescribed antibiotics, including ampicillin and cotrimoxazole, now exceeds 90% in some wound infection cases.
-
Saudi German Hospital Madinah supports life-saving organ donation case in Saudi Arabia
The donated organs were allocated to three patients suffering from advanced organ failure.
-
Archimed to take Esperion Therapeutics private in US$1.1B cardiometabolic deal
The transaction is expected to close in the third quarter, after which Esperion will delist from the Nasdaq and operate as a privately held company.
-
-
LEO Pharma acquires Replay to advance their gene therapy pipeline for rare genetic skin diseases
LEO Pharma will gain access to Replay’s proprietary high-payload herpes simplex virus (HSV) delivery platform, an innovative technology designed to deliver large therapeutic genes directly into skin cells.